Approximately one-quarter of patients with schizophrenia are affected by tardive dyskinesia (TD), a serious, and potentially disabling, movement disorder. Since the first cases were reported in 1957, much has been learned about risk factors and existing treatment options. However, further research is needed to fully understand the epidemiology of TD and the potential of novel treatment strategies.

Download this educational supplement to briefly review key recent and seminal articles that discuss:

• Screening instruments and guidelines
• Genetic and non-genetic risk factors
• Leading hypotheses for the epidemiology of TD
• Available treatment options and emerging therapies

Read the Supplement